Posted by Michael Wonder on 04 Apr 2026
European Commission approves Keytruda (pembrolizumab) plus paclitaxel ± bevacizumab for the treatment of adults with PD-L1 (CPS ≥1) platinum-resistant recurrent ovarian carcinoma who have received one or two prior systemic treatment regimens
2 April 2026 - Merck announced that Keytruda (pembrolizumab), in combination with paclitaxel, with or without bevacizumab, is approved in the European Union for the treatment of platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal carcinoma in adults whose tumours express PD-L1 with a combined positive score ≥1 and who have received one or two prior systemic treatment regimens.
This approval, which also covers KEYTRUDA SC [known as Keytruda Qlex (pembrolizumab and berahyaluronidase alfa-pmph) in the US], makes this regimen the first and only PD-1 inhibitor-based treatment option for eligible patients with platinum-resistant ovarian cancer in the European Union.
